biosimilars Latest News

SMi is pleased to announce the 16th annual Generics and Patent Strategies conference taking place in London from 13-14 May 2013. The conference will see world-renowned experts present the hottest topics and key challenges faced within the industry

engageIndia has partnered with the ultimate global forum on Lifesciences, BioAsia, India to connect, discuss, explore and drive a bio-future poised to be shaped by the next industry trends: Biologics and Biosimilars.

Variations in global regulatory strategy for biosimilars outside Europe, Japan and the US

Biosimilars for recombinant human insulin and insulin glargine

Held in association with Interpharm | 17 July 2013, London,...

SMi is pleased to announce the 16th annual Generics and Patent Strategies conference taking place in London from 13-14 May 2013. The conference will see world-renowned experts present the hottest topics and key challenges faced within the industry

engageIndia has partnered with the ultimate global forum on Lifesciences, BioAsia, India to connect, discuss, explore and drive a bio-future poised to be shaped by the next industry trends: Biologics and Biosimilars.

Variations in global regulatory strategy for biosimilars outside Europe, Japan and the US

Biosimilars for recombinant human insulin and insulin glargine

BioPharma India- Today to Future 2020 seeks to provide platform for the leaders from Biologics,Biosimilars and Health Management Services to exchange insight towards challenges and opportunities waiting to be converted to the next blockbuster level

A new report by visiongain, a London-based business information company, predicts that global revenues for biosimilars will reach $1.6 billion in 2012.

Bharatbook from its exhaustive collection has come out with a report " Biosimilars : Current Situation & Future Prospects, Worldwide " which gives an overview, Demand, Supply Trends and industry analysis reports.

Vice Presidents and Directors of Big Pharmas – Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen, Merck, Novartis, Novo Nordis, Pfizer, Roche, Sanofi and many more will speak at the 2nd Diabetes Summit

Conferences and exhibitions provide networking opportunities with leaders from all sectors of biotechnology and pharmaceuticals.

Seamlessly Integrated R&D, Production, Sales and Marketing Processes to Ensure Success in this High Growth Market

Patent Expiry of Several Key Blockbuster Drugs worth $ 150 billion between 2010 and 2017 Sets Stage for Entry of Generics Manufacturers

Report Buyer, the online destination for business intelligence for major industry sectors, has added a new report.

The biotech market in South Korea is forecasted to grow at a CAGR of around 35% during 2010-2013, says RNCOS in its latest research study.

A new report from IMARC Group expects the US biosimilar market to reach revenues worth US$ 11.4 Billion by 2020. This market, however, unlike small molecule generics, is expected to be a marathon and not a sprint.

Driven by a strong growth in the sales of temperature sensitive healthcare products, IMARC Group expects the global healthcare cold chain logistics market to grow robustly in the coming years.

With billions of dollars worth of biologic drugs going off patient in the next decade, this industry is set to expand at an intensive rate, and the importance of being fully informed of how you and your business will be affected is paramount.

The South Korean biotech industry is expected to grow at a CAGR of around 35% during 2010-2013, thereby contributing majorly to the Asia Pacific biotech market, says RNCOS in its latest research.

The Asia Pacific biotech market is expected to grow at a CAGR of around 19% during 2010-2013 on the back of demographic factors and increasing investments in the industry, says RNCOS.

With billions of dollars worth of biologic drugs going off patient in the next decade, this industry is set to expand at an intensive rate, and the importance of being fully informed of how you and your business will be affected is paramount.

Attend the one event where the industry leaders driving the business of biosimilars unite to set the standards which will shape an evolving legal and regulatory landscape

GPCR & Kinase Targets Advances in drug discovery from molecular to clinical 14th - 15th April 2011, Thistle City Barbican, London, UK

The report provides extensive information and rational analysis of the global monoclonal antibodies market.

New Pharmaceuticals research report from Business Insights is now available from Fast Market Research

Aarkstore.com announce a new report "Global Biosimilars (Follow-on biologics) Market: An Analysis " through its vast collection of market research report.

Bharatbook added a new report on "Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025" which predicts how the biosimilars market will develop from 2010 onwards.

La Cátedra Curaxys se dedicará al desarrollo de medicamentos biológicos, y a la formación de investigadores y gestores especializados en biotecnología

Recently published report Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 will provide you with information that you need to understand current trends and future possibilities for those drugs.

U.S. legal situation holding market back

Fast Market Research recommends "The Global Active Pharmaceutical Ingredients (API) Market: Evaluating challenges, opportunities, innovations and the market environment" from Business Insights, now available

How have recent shifts in the health care reform debate changed the outlook of biosimilars legislation, and how could inappropriate legislation stifle the innovation inherent in the biotech industry? The experts weigh in.

The report provides insights on the biosimilars market revenues and growth until 2015. Further, the distribution of revenues across key geographies such as the US, the top five countries in Europe and Japan are provided in the report...

A multidisciplinary team of researches specialized on Biotechnology, Biomedicine, Science and Environmental sciences, will research in new processes for the biosimilars production.

Un equipo multidisciplinar de la Universidad, de Biotecnología, Ciencias y Medio Ambiente, investigará en productos biogenéricos

The biosimilars production has been incorporate to the new technological platforms of Curaxys in order to get more competitive processes and products. Curaxys has been pioneer in the use of those technologies, mainly in the baculovirus expression sys

Curaxys is the new company specialized in the production of biosimilars medicines. It is an independent private company, located on the technological park of Cadiz (Spain). The new venture is focuses in the development of new technological platform f

Bharatbook.com added a new report on "Europe Active Pharmaceuticals Ingredients Market Analysis and Forecasts to 2020" focus the Growth Of The Innovative Sector Of The Synthetic API Market In Europe.

Bharatbook.com included " Biosimilars and Biobetters: Positioning for a New Market " that provides information on biosimilars and production of therapeutic peptides and proteins

Monoclonal antibodies in cancer therapy – significant commercial opportunities with developing technologies and innovative products – our new report explains prospects

There is great demand for lower-cost biological drugs: commercial and regulatory developments will make biosimilars and follow-on biologics a success – our new report explains how- Revenues for biologic drugs reached approximately $125bn in 2008.

Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has added a new report which provides an up-to-date overview of the latest changes within the global generic market over the last 18 months.

Report Buyer, the online destination for business intelligence for major industry sectors, has added a new report which says Europe is far ahead of the U.S when it comes to approving the use of biosimilars.